Report #2857480

Received Sep 9, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: Age unknown
State: PA
Recovered: Unknown
Vaccinated: Sep 3, 2025
Onset: Sep 3, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	UNK	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Inappropriate schedule of vaccine administered; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (First dose was received in SEP-2024). On 03-SEP-2025, the patient received the 2nd dose of Shingrix. On 03-SEP-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Inappropriate schedule of vaccine administered). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 03-SEP-2025 The patient was scheduled to receive his second dose the morning of 3rd September 2025.